Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System
| Autor: | Adam M Dimmick, Vishnu C. Ramani, Clementine A. Lemaire, Nasim A Barzanian, Robert F. Englert, Steve C. Crouse, Corinne Renier, Michael Lee Kochersperger, Stephan Hengstler, Sean Z Liu, Elodie Sollier-Christen, Michael W Chiu, Charles Wilkerson, Stefanie S. Jeffrey, James Che, Dino Di Carlo, Meghah Vuppalapaty, Kuo-Wei Huang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microfluidics Population Cell Cell Separation 03 medical and health sciences 0302 clinical medicine Circulating tumor cell medicine Humans Fluidics Liquid biopsy education Whole blood Automation Laboratory education.field_of_study Blood Cells Liquid Biopsy Reproducibility of Results Neoplastic Cells Circulating Computer Science Applications Medical Laboratory Technology 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer cell Biomedical engineering |
| Zdroj: | SLAS Technology. 23:16-29 |
| ISSN: | 2472-6303 |
| Popis: | Tumor tissue biopsies are invasive, costly, and collect a limited cell population not completely reflective of patient cancer cell diversity. Circulating tumor cells (CTCs) can be isolated from a simple blood draw and may be representative of the diverse biology from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis. We present here the transition from a cutting-edge microfluidic innovation in the lab to a commercial, automated system for isolating CTCs directly from whole blood. As the technology evolved into a commercial system, flexible polydimethylsiloxane microfluidic chips were replaced by rigid poly(methyl methacrylate) chips for a 2.2-fold increase in cell recovery. Automating the fluidic processing with the VTX-1 further improved cancer cell recovery by nearly 1.4-fold, with a 2.8-fold decrease in contaminating white blood cells and overall improved reproducibility. Two isolation protocols were optimized that favor either the cancer cell recovery (up to 71.6% recovery) or sample purity (≤100 white blood cells/mL). The VTX-1's performance was further tested with three different spiked breast or lung cancer cell lines, with 69.0% to 79.5% cell recovery. Finally, several cancer research applications are presented using the commercial VTX-1 system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|